NOVARTIS: Fevipiprant will not go beyond phase III in asthma | BUY | CHF107 vs. CHF108 (+17%)
NOVARTIS - BUY | CHF107 vs. CHF108 (+17%)Fevipiprant will not go beyond phase III in asthma
Pooled analyses of LUSTER do not support further development
Limited impact on forecasts but more significant on sentiment
Is the future of Respiratory within Novartis called in question?
A good piece of news for competitors
Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.